Eli Lilly & Co. posted a 4% decline in second-quarter revenue, driven by a drop in sales of the company’s Covid-19 antibody treatment.
The pharmaceutical company on Thursday cut its profit outlook for the year as the stronger U.S. dollar impacts results.
Continue reading your article with
a WSJ membership
View Membership Options